Blog

Tara Franks, Chief Operating Officer of TD2, recognized as a 2023 Phoenix Titan 100

SCOTTSDALE, ARIZONA, UNITED STATES, May 17, 2023 / EINPresswire.com/ — Titan CEO and headline sponsor Wipfli LLP are pleased to announce Tara Franks, Chief Operating Officer of Translational Drug Development (TD2), as a 2023 Phoenix Titan 100. The Titan 100 program recognizes Phoenix’s Top 100 CEO’s & C-level executives. They are the area’s most accomplished...

Read more +

TD2 to Highlight the Development of a Novel Metabolomic Cancer Model at the AACR Annual Meeting 2023

SCOTTSDALE, ARIZONA, UNITED STATES, April 11, 2023/EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract...

Read more +

SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage...

Read more +

SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...

Read more +

Genzada Pharmaceuticals Opens Phase 1B Metastatic Breast Cancer Trial

HUTCHINSON, Kan. – May 12, 2022 – Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA, announced today the...

Read more +

View More
Skip to content